Insomnia Market Forecasts to 2028 – Global Analysis By Type of Diseases (Poor Quality of Sleep, Sleep Maintenance), Route of Administration (Oral Mists, Parenteral) and By Geography

Insomnia Market Forecasts to 2028 – Global Analysis By Type of Diseases (Poor Quality of Sleep, Sleep Maintenance), Route of Administration (Oral Mists, Parenteral) and By Geography

According to Stratistics MRC, the Global Insomnia Market is accounted for $5124.04 million in 2021 and is expected to reach $7807.44 million by 2028 growing at a CAGR of 6.2% during the forecast period. Insomnia is a common sleep disorder characterized by difficulties in sleep. Insomnia can exist as alone or conjugated with other psychiatric problems. The exact reason for the cause of insomnia is still unknown. It is most common in women and the severity may increase in conditions like postpartum, menopause and pregnancy. Insomnia disorder can be diagnosed in sleep laboratories using various diagnostic devices.

Market Dynamics:

Driver:

Increasing Stress in Work Place

The work conditions are presently a lot of stress for the employees which is further resulting in tension, constant thinking, and loss of sleep. Also, the market is witnessing a huge demand for OTC drugs amongst the different age groups of patients that are suffering from insomnia. Also, owing to the rising incidence of insomnia amongst people due to numerous reasons like tension and stress is likely to act as major drivers for the global growth of the market.

Restraint:

Lack of Clinical Training

Lack of in-depth clinical training in current medical curricula has resulted in delayed or misdiagnosed and improper treatment plans for patients. An increased understanding and screening of insomnia disorder by health care professionals could result in broader public knowledge of insomnia disorder and sleep health.

Opportunity:

Development of New Technologies

The development of new technologies and the introduction of medical devices are anticipated to boost the market growth. The major market players are playing a significant role in the market. For instance, Eisai Co. Ltd received approval from the US Food and Drug Administration (FDA) and the firm launched its in-house discovered orexin receptor antagonist DAYVIGO (lemborexant) CIV for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance in the United States.

Threat:

Strict Condition

As insomnia’s drugs can be prescribed by doctors only in special cases and under strict conditions, like morphine. These prescriptions are strictly determined by distribution and storage licenses and laws which act ac a major threat for the growth of the market.

Benzodiazepines segment is expected to be the largest during the forecast period

Benzodiazepines are a type of sedative medication. This means they slow down the body and brain's functions. They can be used to help with anxiety and insomnia (difficult getting to sleep or staying asleep) Benzodiazepines are a group of CNS depressants which induce feelings of calm (anxiolysis), drowsiness and sleep. They act by facilitating the binding of the inhibitory neurotransmitter GABA at various GABA receptors throughout the CNS.

The over-the-counter segment is expected to have the highest CAGR during the forecast period

The over-the-counter sleep aids segment is going to have lucrative growth during the forecast period attributing to the growth of this market includes easier availability, low prices, and publicity regarding the side effects of the prescription sleep aids has also steered the patients towards over-the-counter sleep aid.

Region with highest share:

The North America is projected to hold the highest market share, owing to the growing need for sleep disorder treatment in the US and Canada coupled with the growing prevalence of sleep disorders is driving the market. According to the American Academy of Sleep Medicine 2020, stress can result in adjustment insomnia, which may affect up to 20% of people in the United States each year. Poor sleeping habits in children lead to behavioural insomnia of childhood, affecting 30% of children. Prescription drugs, substance abuse, medical disorders, and mental health conditions cause insomnia, with about 3% of the population having this type of sleep issue. Specific causes include depression, drug withdrawal, obesity, and anaemia.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR. The market expansion in this province can be highly attributed to increased stress level of working population along with shift-work related sleep disorders. Asia-Pacific excluding Japan (APEJ) will also remain a remunerative region for growth of the market Governments in the province are constantly focusing on improving their healthcare system along with the provision of favourable reimbursement policies, which in turn might impact the insomnia market.

Key players in the market:

Some of the key players profiled in the Insomnia Market include Astellas, Biocodex S A, Consumer Healthcare Inc., Dainippon Sumitomo, ECR Pharmaceuticals, Eisai Co., Flynn Pharma, Johnson & Johnson, Meda Consumer Healthcare Inc., Merck & Co. Inc., Neurim, Pernix Therapeutics, Pfizer Inc., Purdue Pharma L.P., Sanofi Pasteur, SkyePharma, Takeda Pharmaceutical Company, Vanda Pharmaceuticals Inc. Zydus Cadila, Minerva Neurosciences Inc.

Key developments:

In in June 2020: Eisai Co. Ltd launched in-house discovered orexin receptor antagonist DAYVIGO (lemborexant) CIV for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. All these factors are projected to increase the growth of the insomnia treatment market in the North Amer.

In July 2019: Zydus Cadila launched Ramelteon tablets, used to treat insomnia, in the US market.

In January 2021: Minerva Neurosciences Inc. and Royalty Pharma plc entered into an agreement under which Royalty Pharma will acquire Minerva’s royalty interest in seltorexant. Seltorexant, a selective orexin 2 receptor antagonist, is currently in Phase 3 development for the treatment of major depressive disorder (MDD) with insomnia symptoms.

Type of Therapy’s Covered:
Non Pharmacological Therapy
Pharmacological Therapy

Type of Disease’s Covered:
Poor Quality of Sleep
Sleep Maintenance

Route of Administrations Covered:
Oral Mists
Parenteral

Drug Formulations Covered:
Capsules
Tablet

Drug Classes Covered:
Antidepressants
Benzodiazepines

Applications Covered:
Female
Male
Senior Citizens

Distribution Channels Covered:
Drug Stores
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies

End Users Covered:
Homecare
Medical Devices
Specialty Clinics

Regions Covered:
North America
US
Canada
Mexico
Europe
Germany
UK
Italy
France
Spain
Rest of Europe
Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
South America
Argentina
Brazil
Chile
Rest of South America
Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025 and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
Company Profiling
Comprehensive profiling of additional market players (up to 3)
SWOT Analysis of key players (up to 3)
Regional Segmentation
Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances